ACLARIS THERAPEUTICS INC. - COMMON STOCK

Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

10 May 2022 07:00:02 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium

03 May 2022 07:00:01 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

24 Feb 2022 07:00:02 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference

02 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Expands Leadership Team

01 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Provides R&D Update

11 Jan 2022 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference

27 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine

03 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021

18 Nov 2021 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

03 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

02 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action

27 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

26 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

05 Aug 2021 07:00:02 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021

08 Jul 2021 07:00:00 By Nasdaq GlobeNewswire

Aclaris Announces Pricing of Public Offering of Common Stock

09 Jun 2021 19:55:14 By Nasdaq GlobeNewswire

Aclaris Announces Proposed Public Offering of Common Stock

08 Jun 2021 16:15:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

08 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

17 May 2021 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update

07 May 2021 07:00:01 By Nasdaq GlobeNewswire